X
[{"orgOrder":0,"company":"Amzell B.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amzell to Begin Phase 3 Trial of AMZ002 to Treat Infantile Epileptic Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"NETHERLANDS","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Amzell B.V"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Kynexis Therapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
KYN-5356 is a clinical-stage small molecule targeting a key enzyme in the kynurenine pathway known as KAT-II. It is being evaluated in phase 1 clinical trials for the treatment of cognitive impairment associated with schizophrenia (CIAS).
Lead Product(s):
KYN-5356
Therapeutic Area: Neurology
Product Name: KYN-5356
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 04, 2024
Details:
The phase 3 trial will compare AMZ002 to another active treatment in a superiority study, as a placebo-controlled trial would not be ethical for this patient population.
Lead Product(s):
AMZ002
Therapeutic Area: Neurology
Product Name: AMZ002
Highest Development Status: Phase I
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 27, 2020